- Home
- DBX vs ACLX Comparison
DBX vs ACLX Comparison
Compare DBX & ACLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$22.70
HOLD
Current Price
$114.88
Company Overview
Basic Information| Metric | DBX | ACLX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.7B |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | DBX | ACLX |
|---|---|---|
| Price | $22.70 | $114.88 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 15 |
| Target Price | $28.14 | ★ $115.85 |
| AVG Volume (30 Days) | ★ 3.1M | 1.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.86 | N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | N/A | ★ $22,286,000.00 |
| Revenue This Year | $0.20 | $411.22 |
| Revenue Next Year | N/A | $138.37 |
| P/E Ratio | $12.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.70 | $47.86 |
| 52 Week High | $32.40 | $114.94 |
Technical Indicators
Market Signals| Indicator | DBX | ACLX |
|---|---|---|
| Relative Strength Index (RSI) | 38.76 | 80.84 |
| Support Level | $22.00 | $66.06 |
| Resistance Level | $29.95 | N/A |
| Average True Range (ATR) | 0.74 | 0.16 |
| MACD | -0.02 | -1.09 |
| Stochastic Oscillator | 36.69 | 89.36 |
Price Performance
Historical Comparison DBX
ACLX
About DBX Dropbox Inc.
Dropbox provides cloud storage and content collaboration tools, focusing on individuals and small to midsize businesses. Founded in 2007, Dropbox was a pioneer in the file sync and share market. In recent years, the firm has been emphasizing its Dash product, which facilitates AI-powered universal search across unstructured cloud data.
About ACLX Arcellx Inc.
Arcellx Inc a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases. Its pipeline includes Multiple Myeloma, Acute Myeloid Leukemia, Non-Oncology, and Solid Tumors.